PER45 Antibody

What is CD45 and why is it a significant target for antibodies in research?

CD45 is a protein tyrosine phosphatase expressed on the surface of all nucleated hematopoietic cells and plays a central role in modulating lymphocyte function. As a transmembrane glycoprotein, CD45 exists in multiple isoforms due to alternative splicing of exons encoding the extracellular domain. CD45 antibodies are critical research tools because they allow for the identification and isolation of specific lymphocyte populations. In particular, CD45 is essential for signal transduction in B and T lymphocytes, making CD45 antibodies valuable for studying immune cell development, activation, and function . The B cell-specific glycoform of CD45, known as B220, is especially important as it serves as a marker for B cell lineage cells and is recognized by specific antibodies used in flow cytometry and immunohistochemistry .

How do CD45 antibodies differ from other immune cell surface marker antibodies?

CD45 antibodies are distinguished from other immune cell marker antibodies by their ability to recognize multiple isoforms of the same protein. While many surface markers are expressed on limited cell populations, CD45 is present on all leukocytes, though in different isoforms. According to research findings, specific CD45 antibody clones can distinguish between these isoforms, making them uniquely versatile for immunophenotyping. For example, antibodies targeting B220 (CD45R) specifically identify B-lineage cells in mice, as the RA3-6B2 clone recognizes a B220-specific glycoform of CD45 . In contrast, other immune cell marker antibodies typically recognize single proteins with limited isoform variants. Additionally, CD45 antibodies can identify developmentally regulated glycoforms, such as the N-linked N-acetyllactosamine determinant preferentially expressed on naive B cells that is sterically masked by sialic acid on B220-positive memory B cells .

What are the common formats of CD45 antibodies available for research?

CD45 antibodies are available in multiple formats to suit various experimental applications. Common formats include:

For instance, PerCP/Cyanine5.5-conjugated anti-mouse CD45R/B220 antibodies are specifically designed for flow cytometry applications, allowing researchers to identify B cells in complex samples . Research facilities typically select the appropriate format based on their specific experimental requirements and available detection systems.

How can CD45 antibodies be used to distinguish naive from memory B cells?

CD45 antibodies provide a powerful tool for distinguishing naive from memory B cells based on differential glycosylation patterns. Research has demonstrated that CD45/B220 is expressed in more than 90% of all human naive B cells but in only approximately 20% of memory B cells . This distinction occurs because naive B cells express a specific N-linked N-acetyllactosamine determinant on their CD45 molecules that is recognized by certain antibodies, particularly those encoded by VH4.34 genes .

To effectively distinguish these populations:

• Use flow cytometry with anti-CD45R (B220) antibodies in conjunction with other B cell markers

• Apply a dual staining approach with anti-IgD (high on naive B cells) and anti-CD27 (high on memory B cells)

• Analyze the expression patterns to identify B220high/IgDhigh/CD27low cells (naive) versus B220low/IgDlow/CD27high cells (memory)

This methodology is particularly useful in studying B cell maturation, activation status, and immune memory development. Researchers should be aware that sialic acid on B220-positive memory B cells sterically masks the N-acetyllactosamine determinant, resulting in differential binding of certain CD45 antibodies between naive and memory populations .

What are the optimal conditions for using CD45 antibodies in flow cytometry?

When using CD45 antibodies in flow cytometry, several key parameters must be optimized:

For multi-color panels, titration of each CD45 antibody conjugate is essential to determine optimal signal-to-noise ratios. Researchers should confirm that their chosen CD45 antibody clone recognizes the specific isoform of interest. For example, when studying mouse B cells, the RA3-6B2 clone conjugated to PerCP/Cyanine5.5 effectively identifies the B220 isoform . Additionally, including proper compensation controls is crucial when CD45 antibodies are used in panels with spectrally overlapping fluorochromes.

How should CD45 antibodies be validated before use in critical experiments?

Rigorous validation of CD45 antibodies is essential for generating reliable research data. A comprehensive validation workflow includes:

• Specificity testing: Confirm binding to the intended CD45 isoform using positive and negative control cells. Validation studies should include testing on CD45-knockout cells or tissues as negative controls and cell lines with known CD45 expression patterns as positive controls.

• Cross-reactivity assessment: Test the antibody against cell types that should not express the target CD45 isoform, including cells from other species if cross-reactivity claims are made by the manufacturer.

• Functional validation: For blocking antibodies, confirm inhibition of CD45 phosphatase activity using appropriate enzyme assays or downstream signaling readouts.

• Lot-to-lot consistency: When receiving new lots, compare performance to previously validated lots using standard samples.

• Multi-method confirmation: Validate antibody performance across the intended applications (flow cytometry, Western blot, immunoprecipitation) using consistent samples.

For example, researchers studying lupus autoantibodies conducted comprehensive biochemical studies to conclusively demonstrate that lupus IgG VH4.34 antibodies target a developmentally regulated B220-specific glycoform of CD45 . This validation included depletion experiments to confirm specificity and glycoform recognition patterns.

How do CD45 antibodies contribute to understanding autoimmune diseases?

CD45 antibodies have become essential tools for investigating autoimmune pathogenesis, particularly in conditions where anti-lymphocyte autoantibodies are prevalent. In systemic lupus erythematosus (SLE), researchers have used CD45 antibodies to make several critical discoveries:

• Autoantigen identification: Studies have conclusively demonstrated that lupus IgG VH4.34 antibodies target a B220-specific glycoform of CD45, specifically an N-linked N-acetyllactosamine determinant preferentially expressed on naive B cells .

• Autoantibody specificity: The reactivity to CD45 isoforms in SLE sera is restricted to VH4.34 antibodies and can be eliminated by depleting these antibodies, suggesting a selective autoimmune response .

• B cell developmental abnormalities: By using CD45 antibodies to track B cell maturation stages, researchers have identified disruptions in B cell development and survival in autoimmune conditions.

These findings suggest that the carbohydrate moiety recognized by VH4.34 antibodies may act as a selecting antigen in SLE pathogenesis . Researchers can employ CD45 antibodies in combination with other markers to monitor changes in lymphocyte populations during disease progression and therapeutic intervention, providing valuable insights into treatment efficacy and disease mechanisms.

What methodological approaches can resolve contradictory CD45 antibody staining patterns?

Researchers occasionally encounter contradictory staining patterns when using CD45 antibodies, which can arise from multiple factors. Resolving these discrepancies requires systematic troubleshooting:

• Epitope masking assessment: Investigate whether post-translational modifications affect antibody binding. For example, research has shown that sialic acid sterically masks the N-acetyllactosamine determinant on B220-positive memory B cells, affecting antibody recognition . Researchers can use neuraminidase treatment to remove sialic acid residues and test if this resolves discrepant staining patterns.

• Clone-specific binding characteristics: Different antibody clones may recognize distinct epitopes on CD45 molecules. Compare results using multiple antibody clones targeting different CD45 epitopes.

• Fixation/permeabilization effects: Test whether your sample preparation method affects CD45 epitope accessibility. Compare results using different fixation protocols (e.g., paraformaldehyde vs. methanol vs. fresh cells).

• Competitive binding analysis: If using multiple CD45 antibodies simultaneously, perform sequential staining experiments to identify potential competitive binding or steric hindrance.

• Single-cell analysis: Employ single-cell approaches like mass cytometry or spectral flow cytometry to resolve complex expression patterns at higher resolution.

In cases where distinct antibody clones yield different results, researchers should consider reporting both findings and discussing the potential biological significance of these differences, as they may reflect meaningful heterogeneity in CD45 isoform expression or modification.

How can CD45 antibodies be integrated into multi-parameter single-cell analysis platforms?

Integrating CD45 antibodies into advanced single-cell analysis platforms requires strategic panel design and technical optimization:

For successful integration:

• Panel design: Position CD45 antibodies as lineage-defining markers in your panel. In mass cytometry, assign abundant metals to CD45 antibodies if they're used for broad leukocyte identification.

• Titration optimization: Determine optimal concentrations specific to each platform, as requirements differ significantly between flow cytometry and mass cytometry.

• Batch normalization: Include CD45 antibodies in reference samples used for batch alignment, as their broad expression makes them useful normalization markers.

• Computational analysis: Leverage CD45 expression in algorithm-assisted population identification. For example, in unsupervised clustering approaches, CD45 expression can help distinguish hematopoietic from non-hematopoietic populations.

Researchers using single-cell RNA sequencing with CITE-seq can simultaneously detect CD45 protein expression and transcript levels, enabling correlation analyses between protein and mRNA expression for CD45 and its isoforms. This approach provides insights into post-transcriptional regulation of CD45 splicing variants in different immune cell populations.

How are technological developments enhancing CD45 antibody applications?

Recent technological advances have significantly expanded the utility of CD45 antibodies in immunological research:

• Recombinant antibody production: The shift toward recombinant antibody technologies has improved lot-to-lot consistency of CD45 antibodies, ensuring more reproducible results across studies. Expression systems like Chinese hamster ovary (CHO) cells now enable consistent production of high-quality antibodies .

• Multicolor spectral flow cytometry: Advanced flow cytometry platforms now allow simultaneous use of multiple CD45 antibody clones conjugated to spectrally similar fluorochromes, enabling detailed analysis of CD45 isoform co-expression through spectral unmixing.

• Antibody engineering: Structure-guided modifications have produced CD45 antibodies with enhanced specificity for particular isoforms. Similar to approaches used for therapeutic antibodies, researchers can now access CD45 antibodies with modified Fc regions to prevent unwanted Fc-mediated effects during functional studies .

• Nanobody and single-domain antibody development: These smaller antibody fragments offer superior tissue penetration for imaging applications and can access epitopes that might be sterically hindered for conventional antibodies.

• Photoswitchable and photoactivatable conjugates: CD45 antibodies conjugated to these advanced fluorophores enable super-resolution microscopy studies of CD45 distribution and dynamics at the immune synapse.

These technological developments allow for more sophisticated experimental designs, enabling researchers to address previously intractable questions about CD45 biology and function in normal and pathological immune responses.

What novel insights have CD45 antibodies provided about lymphocyte development and function?

CD45 antibodies have been instrumental in revealing fundamental aspects of lymphocyte biology:

• Lineage commitment markers: Research using CD45 isoform-specific antibodies has demonstrated that CD45 isoform switching occurs during lineage commitment and activation. The B cell-specific glycoform B220 (CD45R) is expressed on >90% of naive B cells but only ~20% of memory B cells, providing crucial insights into B cell maturation .

• Signaling regulation: Studies utilizing blocking CD45 antibodies have elucidated the role of CD45 phosphatase activity in setting thresholds for antigen receptor signaling. These findings have transformed our understanding of lymphocyte activation requirements.

• Developmental checkpoints: Flow cytometric analysis with CD45 antibodies has identified critical developmental checkpoints in lymphocyte maturation. For instance, the differential expression of CD45 isoforms marks distinct stages of B cell development from pro-B to mature B cells.

• Functional heterogeneity: CD45 antibody staining has revealed unexpected functional heterogeneity within seemingly homogeneous lymphocyte populations, challenging previous paradigms of lymphocyte classification.

• Disease-associated modifications: Research using CD45 antibodies has identified disease-specific post-translational modifications, such as the N-linked N-acetyllactosamine determinant recognized by lupus autoantibodies, suggesting potential disease mechanisms in autoimmunity .

These insights continue to refine our understanding of lymphocyte biology and provide new conceptual frameworks for investigating immune regulation in health and disease.

How might CD45 antibodies contribute to emerging immunotherapeutic approaches?

CD45 antibodies are poised to make significant contributions to next-generation immunotherapeutic strategies:

• CAR-T cell engineering: Researchers are exploring CD45 isoform-specific antibodies to isolate and expand specific T cell subsets with enhanced persistence or effector function for CAR-T manufacturing. The ability to distinguish naive from memory populations using CD45 antibodies may improve the generation of stem-like CAR-T cells with superior therapeutic potential.

• Immune monitoring: CD45 antibody panels are being developed for comprehensive immune monitoring during immunotherapy, providing crucial information about treatment effects on specific lymphocyte subsets. Similar to approaches used with other therapeutic antibodies, these panels can track changes in immune populations during treatment .

• Targeted drug delivery: CD45 antibodies conjugated to nanoparticles or liposomes could enable selective delivery of immunomodulatory compounds to specific leukocyte populations. This approach builds on the established antibody-drug conjugate (ADC) technology used in cancer therapeutics .

• Depletion therapies: Isoform-specific CD45 antibodies could potentially enable selective depletion of pathogenic lymphocyte subsets while sparing regulatory populations. This strategy would extend the concept of targeted immunomodulation demonstrated with other therapeutic antibodies .

• Checkpoint modulation: Emerging research suggests that CD45 functions as an immune checkpoint molecule in certain contexts. Antibodies that modulate CD45 phosphatase activity could represent a novel class of checkpoint modulators distinct from current PD-1/CTLA-4-targeted approaches.

While these applications remain largely experimental, they represent promising directions for translating fundamental insights gained from CD45 antibody research into clinical benefit for patients with cancer, autoimmunity, and infectious diseases.